We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Novel Strategy for Tuberculosis Vaccine
News

Novel Strategy for Tuberculosis Vaccine

Novel Strategy for Tuberculosis Vaccine
News

Novel Strategy for Tuberculosis Vaccine

Credit: Triggermouse/ Pixabay
Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Novel Strategy for Tuberculosis Vaccine"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Innovators at Purdue University and Houston Methodist Research Institute have created a novel strategy for developing an effective vaccine for a widespread form of tuberculosis.

Mycobacterium tuberculosis (Mtb) is a leading cause of death worldwide, leading to over 1.5 million fatalities annually. Approximately one-third of the global population is infected with the latent form of Mtb. Bacillus Calmette-Guérin (BCG) is widely used as a vaccine against tuberculosis but has a variable protection against neonatal and adult pulmonary TB. That protection can, however, range from zero to 80% among infants. Children are routinely vaccinated, yet Mtb dissemination into brain and tuberculosis meningitis continues to occur.

Purdue and Houston Methodist researchers have created this novel TB vaccine formulation by incorporating autophagy-mediated antigen presentation, which initiates an enhanced T cell response. Chinnaswamy Jagannath, professor of pathology and genomic medicine at the Houston Methodist Research Institute, which is an affiliate of Weill Cornell Medical College, showed that the novel formulation improves the development of tuberculosis-specific immune responses. Jagannath collaborates with Dr. Suresh Mittal, Distinguished Professor of Virology in Purdue's College of Veterinary Medicine.

"Our vaccine approach is equally effective without or with prior vaccination with BCG," Mittal said.

"It is vital since the majority of people in Mtb-endemic countries are already immunized with BCG," Jagannath said.

Mittal's lab studies delivery platforms for vaccines, and Jagannath's lab used the nasal delivery route for this TB vaccine development.

"The great thing about this work with TB is that it can translate to other infectious diseases and possibly cancer immunotherapy," Mittal said.

The innovators have worked with the Purdue Research Foundation Office of Technology Commercialization to patent their technology. The innovators and OTC are looking for partners to continue developing it. The next step for the vaccine formulation is to conduct a vaccine efficacy study in a nonhuman primate model. Mittal said the successful completion of the study will form the basis for a human trial, though no human trial is currently planned.

Reference: Khan A, Sayedahmed EE, Singh VK, et al. A recombinant bovine adenoviral mucosal vaccine expressing mycobacterial antigen-85B generates robust protection against tuberculosis in mice. cell rep med. 2021;2(8):100372. doi: 10.1016/j.xcrm.2021.100372

This article has been republished from the following materials. Note: material may have been edited for length and content. For further information, please contact the cited source.


Advertisement